Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer SubtypesNasim Mavaddat, Christine L. Clarke, Manjeet K. Bolla et al.|The American Journal of Human Genetics|2018Cited by 1.2k
Hyaluronan in Peritumoral Stroma and Malignant Cells Associates with Breast Cancer Spreading and Predicts SurvivalPäivi Auvinen, Veli‐Matti Kosma|American Journal Of Pathology|2000Cited by 496
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer TrialHeikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al.|Journal of Clinical Oncology|2009Cited by 459
Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibilityTuomo Mantere, Katri Pylkäs, Anna Tervasmäki et al.|Scientific Reports|2017Cited by 37